

Neurokaire Abstract

Talia Cohen Solal

Company name: Neurokaire **Website:** <https://www.neurokaire.com/>

CEO name: Talia Cohen Solal **Cell phone number & Email :** +972-50-321-9656 / talia@neurokaire.com

CATEGORY: Biotech/Pharma

SESSION: "From Detection to Prediction: Diagnosing Disease Before Symptoms."

- Executive Summary / Investment Rational

NeuroKaire is a precision medicine company for CNS, utilizing patient-derived neurons from pluripotent stem cells to predict medication response for treatment optimization and effective drug development. Leveraging this technology as a platform, NeuroKaire helps pharma companies' de-risk and improve success rates for new drug development. This past year we launched BrightKaire, a blood-based test to help patients suffering from depression.

- Core Technology:

Our "brain in a dish" technology requires only a simple blood test to determine which antidepressant treatment is best suited for a patient using our innovative stem cell technology. We are able to combine this unique technology with patient genetics and patient history, bringing the predictive power of our platform to an unprecedented 79.3% accuracy.

- Product Profile/Pipeline:

NeuroKaire has successfully launched BrightKaire and is now focused on scaling access, improving workflows, and deepening clinical integration.

In 2026, the company is expanding across:

- Telehealth platforms, enabling broader patient access nationwide
- Enterprise healthcare systems and behavioral health networks, supporting adoption at scale
- Provider partnerships, enhancing clinical decision-making in real-world settings

In parallel, NeuroKaire continues to advance its platform through pharmaceutical collaborations, including expanding applications into Alzheimer's disease and other CNS indications. The company is also actively exploring psychedelic applications in psychiatry, including its partnership with Compass Pathways, and is seeking additional partners to further develop this emerging area of precision treatment.

- Business Strategy:

NeuroKaire operates a dual business model:

- Clinical Testing (BrightKaire)

Focused on scaling adoption across the U.S. through clinics, telehealth providers, and enterprise partnerships. Each test strengthens NeuroKaire's proprietary dataset and biobank, enabling deeper patient stratification and continuous improvement of predictive performance.

- Pharmaceutical Partnerships (PharmaKaire)

Leveraging the platform to improve drug development by enabling better patient selection, reducing trial risk, and increasing the probability of success. This includes expanding into novel therapeutic areas such as psychedelics, where NeuroKaire is working with partners like Compass Pathways and actively pursuing additional collaborations.

- What's Next?

In 2026, NeuroKaire is focused on scaling and expanding impact:

- Broadening access across the U.S. through telehealth and enterprise partnerships
- Accelerating adoption among mental and behavioral health providers
- Enhancing platform precision, particularly in neuronal imaging and data analytics
- Advancing pharmaceutical partnerships and achieving key development milestones
- Expanding partnerships in emerging therapeutic areas, including psychedelics in psychiatry, to support next-generation treatment development